DDInter1425 DDInter1628
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Pentostatin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pentostatin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pentostatin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroxyurea
Hydroxyurea {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroxyurea
Hydroxyurea {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pentostatin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentostatin {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pentostatin {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pentostatin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Pentostatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pentostatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)